Post on 14-May-2023
1
Myotubes from lean and severely obese subjects with and without type 2 diabetes respond 1
differently to an in vitro model of exercise 2
Yuan Z. Feng1, Nataša Nikolić
1, Siril S. Bakke
1, Eili T. Kase
1, Kari Guderud
1, Jøran 3
Hjelmesæth2,3
, Vigdis Aas4, Arild C. Rustan
1 and G. Hege Thoresen
1,5 4
5 1Department of Pharmaceutical Biosciences, School of Pharmacy, University of Oslo, Norway 6
2The Morbid Obesity Center, Vestfold Hospital Trust, Tønsberg, Norway 7
3Department of Endocrinology, Morbid Obesity and Preventive Medicine, Institute of Clinical 8
Medicine, University of Oslo, Norway 9 4Faculty of Health, Oslo and Akershus University College of Applied Sciences, Oslo, Norway 10
5Department of Pharmacology, Institute of Clinical Medicine, Faculty of Medicine, University of 11
Oslo and Oslo University Hospital, Oslo, Norway 12
13
Corresponding address: 14
Yuan Zeng Feng 15
School of Pharmacy 16
P.O. Box 1068 Blindern 17
0316 Oslo 18
Norway 19
E-mail: y.z.feng@farmasi.uio.no 20
Phone: +47 22845675 21
Fax: +47 22854402 22
23
Running title; Myotubes from different donors respond differently to EPS 24
25
Word count; 249 words (abstract), 4193 words (main text), 1 table and 5 figures 26
27
Articles in PresS. Am J Physiol Cell Physiol (January 21, 2015). doi:10.1152/ajpcell.00314.2014
Copyright © 2015 by the American Physiological Society.
2
ABSTRACT 28
Exercise improves insulin sensitivity and oxidative capacity in skeletal muscles. However, the 29
effect of exercise on substrate oxidation is less clear in obese and type 2 diabetic subjects than in 30
lean subjects. We investigated glucose and lipid metabolism and gene expression after 48 h with 31
low-frequency electrical pulse stimulation (EPS), as an in vitro model of exercise, in cultured 32
myotubes established from lean non-diabetic subjects and severely obese subjects (BMI ≥ 40 33
kg/m2) with and without type 2 diabetes. EPS induced an increase in insulin sensitivity, but did 34
not improve lipid oxidation in myotubes from severely obese subjects. Thus, the EPS-induced 35
increases in insulin sensitivity and lipid oxidation were positively and negatively correlated to 36
BMI of the subjects, respectively. EPS enhanced oxidative capacity of glucose in myotubes from 37
all subjects. Furthermore, EPS reduced mRNA expression of slow fiber-type marker (MYH7) in 38
myotubes from diabetic subjects; however the protein expression of this marker was not 39
significantly affected by EPS in neither of the donor groups. On the contrary, mRNA levels of 40
interleukin-6 (IL-6) and IL-8 were unaffected by EPS in myotubes from diabetic subjects, while 41
IL-6 mRNA expression was increased in myotubes from non-diabetic subjects. EPS-stimulated 42
mRNA expression levels of MYH7, IL-6 and IL-8 correlated negatively with subjects’ HbA1c 43
and/or fasting plasma glucose, suggesting an effect linked to the diabetic phenotype. Taken 44
together, these data show that myotubes from different donor groups respond differently to EPS, 45
suggesting that this effect may reflect the in vivo characteristics of the donor groups. 46
47
48
49
3
INTRODUCTION 50
Physical activity plays an important role in both prevention and treatment of obesity and type 2 51
diabetes (T2D). Skeletal muscle is the largest insulin-sensitive organ in humans, accounting for 52
more than 80 % of insulin-stimulated glucose disposal (15). Physical training leads to extensive 53
adaptations in skeletal muscles (14, 46), but the molecular mechanisms underlying these 54
adaptations are still poorly understood, and there is increasing evidence that some individuals 55
may be inherently less responsive to exercise (20, 53). Regular physical activity not only 56
improves oxidative capacity, such as increased lipid and glucose oxidation (39), but is also 57
known to increase insulin-stimulated glucose uptake (45). The effect of exercise on substrate 58
oxidation is less clear in obese and type 2 diabetic subjects than in lean subjects (37). 59
Impairments have been noted in skeletal muscle glucose and fatty acid oxidation in obesity and 60
T2D in the resting state (6, 29, 30). It is therefore important to determine whether interventions, 61
either exercise or pharmacologically, can effectively reverse this impairment. 62
Plasticity of skeletal muscle in response to regular exercise extends beyond the metabolic 63
changes, and PPARδ (peroxisome proliferator-activated receptor-δ) activation is one of many 64
pathways proposed to be involved in exercise adaptations (15, 35). PPARδ is an important 65
regulator of skeletal muscle metabolism, in particular lipid oxidation. It is well known that 66
endurance exercise increases mitochondrial content (46, 54), and that MHCI (myosin heavy chain 67
type I, slow-twitch oxidative) muscle fibers are associated with higher mitochondrial content 68
compared to MHCII (type II, fast-twitch glycolytic) fibers (32). On the other hand, it is debated 69
whether conversion of muscle type II to type I phenotype actually happens in adult humans (22). 70
4
Moreover, skeletal muscle has been identified as a secretory organ that releases a diversity of 71
biologically active proteins classified as myokines that can have autocrine, paracrine or endocrine 72
functions. Muscle contraction during exercise is a major stimulus of these endocrine functions, 73
and the myokines are thought to mediate beneficial effects of exercise and may have a role in the 74
protection against conditions associated with low-grade inflammation, such as T2D and 75
metabolic syndrome (38, 42, 56). The myokines, interleukin-6 (IL-6) and IL-8 are markedly 76
produced in contracting muscles and, at least for IL-6, released into plasma during the post-77
exercise period (2, 51) when the insulin sensitivity is enhanced (23). It seems that IL-6 works as 78
an energy sensor, and preserves fuel availability during exercise (40) by enhancing insulin-79
stimulated glucose disposal and fatty acid metabolism (10, 55). Interestingly, while IL-6 released 80
from skeletal muscle may promote insulin sensitivity (21), IL-6 secreted from adipose tissue may 81
induce insulin resistance in muscle (41). Thus, while it has become evident that contracting 82
skeletal muscle releases myokines that may influence metabolism and function of muscle tissue 83
and other tissues and organs, the secretion of myokines from obese and/or diabetic muscle is yet 84
to be fully clarified. 85
Previously, we have established an in vitro model of regular exercise of cultured human skeletal 86
muscle cells (myotubes) by applying chronic, low-frequency electrical pulse stimulation (EPS) 87
(36), and thereby enabling the study of exercise-induced cellular mechanisms under controlled 88
conditions. Human myotubes are considered a valid model for studying metabolic disorders as 89
obesity and T2D because perturbances evident in vivo, such as depressed lipid oxidation and 90
insulin resistance, are retained in myotubes in culture (1, 7, 19). After EPS, myotubes established 91
from lean non-diabetic subjects showed an increase in glucose and lipid metabolism as well as 92
indications of fast-twitch glycolytic muscle fibers transformation into slow-type oxidative fibers 93
5
(36), and enhanced expression and release of IL-6 and IL-8 (31, 44, 48). In the present study, we 94
wanted to explore whether there are differences in EPS response on insulin sensitivity, glucose 95
and lipid metabolism and gene expression in myotubes from three groups of donors; lean non-96
diabetic, severely obese non-diabetic and severely obese subjects with established T2D and 97
whether these differences reflect the in vivo characteristics of the donor groups. Moreover, 98
PPARδ agonist and exercise training are shown to act synergistically to increase the content of 99
oxidative muscle fibers, and PPARδ agonists have been proposed as exercise mimetics (35). 100
Therefore, we wanted to explore the combined effect of EPS together with the PPARδ agonist, 101
GW501516, on lipid metabolism as well. 102
103
6
MATERIALS AND METHODS 104
Human myotubes 105
Human myotubes grown from satellite cells were isolated as previously described (18) from the 106
M. obliquus internus abdominis from lean or severely obese subjects. The lean non-diabetic 107
donor biopsies were obtained from subjects donating a kidney at Oslo University Hospital, 108
Norway and the severely obese donor biopsies were obtained from subjects undergoing bariatric 109
surgery at The Morbid Obesity Center, Vestfold Hospital Trust, Norway. The isolation of satellite 110
cells from all biopsies was performed at the same location and by the same researchers. The 111
biopsies were obtained with informed consent and approved by the National Committee for 112
Research Ethics, Oslo, Norway (S-04133 and S-09078d). 113
Classification of the severely obese donors into the two groups; severely obese non-diabetic 114
subjects (SO-nD) and severely obese subjects with T2D (SO-T2D) was based on fasting blood 115
glucose values (≥ 7.0 mmol/L), HbA1c (glycosylated hemoglobin, ≥ 6.5 %) and/or use of one or 116
more antidiabetic drugs. The cells were cultured in DMEM-GlutamaxTM
(5.5 mmol/L glucose) 117
with supplements during proliferation and differentiation as previously described (25). Briefly, at 118
~ 80 % confluence, growth medium was replaced by differentiation medium to induce fusion of 119
myoblasts into multinucleated myotubes. Experiments were performed on cells from passage 120
number 2 to 5 and after 7 days of differentiation. There was no difference in mRNA expression 121
levels of muscle fiber type I marker between the myotubes from lean non-diabetic and severely 122
obese subjects, or between the myotubes from severely obese non-diabetic and diabetic subjects 123
(data not shown). 124
125
7
Electrical pulse stimulation of muscle cells 126
Human myotubes grown on Corning®
CellBIND®
6-well plates (Corning Life-Sciences, 127
Schiphol-Rijk, The Netherlands) were stimulated via carbon electrodes by applying chronic, low-128
frequency EPS (single, bipolar pulses of 2 ms, 30 V, 1 Hz) continuously for the last 48 h of the 129
differentiation period, as previously described (36). Culture media were changed every 12th
or 130
24th
h during EPS. Electrical pulses were generated by a muscle stimulator built at the Electronics 131
Lab, Institute of Chemistry, University of Oslo, Norway. Neither applying EPS for 48 h to the 132
myotubes nor changing the media every 12th
or 24th
h showed differences in floating cells 133
evaluated by microscopic inspection, or by measurement of cell protein content in the three donor 134
groups (data not shown). 135
Immunoblotting 136
After EPS, cells were harvested in Laemmli buffer (0.5 mol/L Tris-HCL, 10 % SDS, 20 % 137
glycerol 10 % β-mercaptoethanol and 5% bromphenyl blue). Total cell lysates were 138
electrophoretically separated on 4-20 % Mini-Protean®
TGX™ gels (BioRad, Copenhagen, 139
Denmark) with Tris/glycine buffer (pH 8.3) followed by blotting to nitrocellulose membrane and 140
incubation with antibodies against total Akt kinase, Akt phosphorylated at Ser473, β-actin, α-141
tubulin (all from Cell Signaling Technology, Beverly, MA), MHCI (Millipore, Billeria, MA), and 142
an OXPHOS antibody cocktail recognizing Complex I subunit NDUFB8, Complex II subunit, 143
Complex III subunit core 2, Complex IV subunit II and ATP synthase subunit alpha (Abcam, 144
Cambridge, UK). Immunoreactive bands were visualized with enhanced chemiluminescence 145
(Chemidoc XRS, BioRad, Denmark) and quantified with Image Lab (version 4.0) software. β-146
8
actin or α-tubulin were used to normalize the protein-antibody signals versus protein loading. 147
Glucose metabolism 148
After EPS, myotubes were exposed to serum-free DMEM supplemented with [14
C(U)]glucose 149
(0.5 μCi/mL, 1 mmol/L, PerkinElmer NEN®
, Boston, MA, US) and 1 mmol/L pyruvate in the 150
presence or absence of 100 nmol/L insulin for 3 h to study basal and insulin-stimulated glycogen 151
synthesis as previously described (16). Glucose oxidation was measured after 3 h incubation, 900 152
µL cell medium was transferred to airtight flasks, and 300 µL of phenyl ethylamine:methanol 153
(1:1, v/v) was added to a center well containing a folded filter paper. Subsequently, 200 µL of 1 154
mol/L perchloric acid was added to the cell medium through the stopper tops using a syringe, as 155
previously described (36). The flasks were placed at room temperature to trap labeled CO2 for 2 h, 156
and radioactivity was counted by liquid scintillation. All data were related to protein content. 157
Fatty acid oxidation 158
Myotubes were treated with 0.1 % DMSO (vehicle) or 10 nmol/L GW501516 for 96 h, and EPS 159
was applied to the cells for the last 48 h of the treatment period. After EPS, the myotubes were 160
exposed to 1 mL of DPBS supplemented with HEPES (10 mmol/L), NaHCO3 (44 mmol/L), 161
[1-14
C]oleic acid (1 µCi/mL, 100 µmol/L, PerkinElmer NEN®
, Boston, MA, US), 40 µmol/L 162
BSA and 1 mmol/L L-carnitine in a 5 % CO2-incubator at 37°C. After 2 h, CO2 and cell-163
associated radioactivity were measured as previously described (36). Briefly, 500 µL of cell 164
medium was transferred to airtight flasks, and 300 µL of phenyl ethylamine:methanol (1:1, v/v) 165
was added to a center well containing a folded filter paper. Subsequently, 100 µL of 1 mol/L 166
perchloric acid was added to the cell medium through the stopper tops using a syringe. The flasks 167
were placed at room temperature to trap labeled CO2 for 2 h. The cells were placed on ice and 168
9
washed twice with PBS, lysed with 0.1 mol/L NaOH, and cell-associated radioactivity was 169
counted by liquid scintillation to determine uptake of oleic acid. All data were related to protein 170
content. 171
Live imaging 172
After EPS, the myotubes were incubated at 37°C and 5 % CO2 with MitoTracker®
Red FM (100 173
nmol/L, Invitrogen, Carlsbad, CA) for 15 min to stain mitochondria, Bodipy 493/503 (2 µg/mL, 174
Invitrogen, Carlsbad, CA) for 15 min to stain neutral lipids and Hoechst 33258 (2.5 µg/mL, 175
Invitrogen, Carlsbad, CA) for 15 min to stain nuclei and washed with PBS in between. Live 176
imaging was carried out as previously described (25). Images were randomly taken in 25-36 177
positions per well with a Scan^R platform (Olympus IX81 inverted fluorescence microscope) 178
equipped with a temperature incubator for long-term live imaging. After gating out aggregates 179
and dead cells, each parameter was determined from about 240 images per donor group (average 180
of 38 ± 4 nuclei per image). MitoTracker®
Red FM and Bodipy 493/503 intensity per image was 181
related to number of nuclei per image since for multinucleated myotubes the absolute number of 182
cells cannot be determined. This is an accepted method to account for differences in cell numbers 183
(13, 28, 34, 36). For the myotubes from L-nD subjects, the cells were also treated with 184
GW501516 for 96 h and EPS was applied to the cells for the last 48 h of the treatment period. 185
Gene expression analysis by qPCR 186
After EPS, total RNA was isolated from the myotubes, and qPCR was performed as previously 187
described (36). Briefly, total RNA from cells was isolated by Agilent Total RNA isolation kit 188
according to the supplier’s protocol. RNA was reverse-transcribed with oligo primers using a 189
PerkinElmer Thermal Cycler 9600 and qPCR was performed using an ABI PRISMT 7000 190
10
Detection System (Applied Biosystems, Warrington, UK). Transcription levels were normalized 191
to the housekeeping genes acidic ribosomal phosphoprotein P0 (36B4) and glyceraldehyde-3-192
phosphate dehydrogenase (GAPDH). The following forward and reverse primers (Molecular 193
Probes, Invitrogen, Carlsbad, CA) were used at concentration of 30 µmol/L, 36B4 (acc. no 194
M17885); GAPDH (acc. no NM_002046); IL-6 (acc.no. NM_000600), IL-8 195
(acc.no.NM_000584.2); MYH7 (acc.no.NM_000257.2). 196
Data presentation and statistics 197
Data are presented as mean ± SEM. Statistical analyses were performed using GraphPad Prism 198
5.0 for Windows (GraphPad Software Inc., San Diego, CA, US). The value n represents the 199
number of different donors used, and each with at least duplicate observations. Two-tailed paired 200
Student’s t-tests were performed to determine the effects of treatments, and unpaired Student’s t-201
tests (independent samples) were performed to determine the difference in effects of EPS 202
between the donor groups. For correlation studies, Spearman correlation analysis was performed. 203
Linear mixed model analysis (LMM, SPSS 20.0.0.1, IBM SPSS Inc., Chicago, IL, US) was used 204
to determine the effect of EPS in OXPHOS experiments. The linear mixed model includes all 205
observations (complex I-V) in the statistical analyses and at the same time take into account that 206
not all observations are independent. P < 0.05 was considered statistically significant. 207
208
11
RESULTS 209
Clinical characteristics of the biopsy donors 210
Clinical characteristics of the donors are presented in Table 1. Fasting plasma glucose and HbA1c 211
were significantly higher in severely obese subjects with T2D (SO-T2D) than in non-diabetic 212
subjects with similar body mass index (SO-nD). Fasting plasma levels of insulin, TAG 213
(triacylglycerol) and HDL (high-density lipoprotein) were not different between the two obese 214
groups. As expected, clinical characteristics of lean non-diabetic subjects (L-nD) were 215
significantly different from severely obese subjects. The age was not significantly different 216
between the three donor groups. 217
Effect of EPS on insulin sensitivity in myotubes 218
Myotubes from severely obese subjects with T2D maintained their diabetic phenotype in culture 219
shown as absence of insulin-stimulated glucose uptake in myotubes from SO-T2D, and further, 220
phosphorylation of Akt tended to be lower in myotubes from SO-T2D compared to SO-nD (4). 221
To examine whether EPS could increase insulin sensitivity, insulin-stimulated phosphorylation of 222
Akt (Ser 473) and glycogen synthesis were measured in myotubes established from lean non-223
diabetic (L-nD), SO-nD and SO-T2D after EPS stimulation. In absence of insulin, 224
phosphorylation of Akt was not affected by EPS (Figure 1A), whereas insulin-stimulated 225
phosphorylation of Akt was significantly increased by EPS in myotubes from SO-T2D (Figure 226
1B). In absence of insulin, glycogen synthesis was not affected by EPS (Figure 1C), whereas 227
insulin-stimulated glycogen synthesis after EPS was increased in myotubes from both SO-nD and 228
SO-T2D subjects (Figure 1D). Further, EPS-induced effect on insulin-stimulated phosphorylation 229
12
of Akt and glycogen synthesis in the myotubes correlated positively with BMI of the subjects 230
(Figures 1E, F), i.e. the EPS effect increased with increasing BMI of the donors. 231
Effect of EPS on glucose and oleic acid metabolism 232
We wanted to explore whether there were differences in the EPS-induced response on oxidative 233
capacity in myotubes established from lean, non-diabetic and severely obese subjects with and 234
without T2D. Glucose oxidation after EPS was increased in myotubes from both lean and 235
severely obese subjects (Figure 2A), whereas EPS had effect on oleic acid oxidation in myotubes 236
from lean subjects only (Figure 2B). Furthermore, oleic acid oxidation after EPS was 237
significantly different in myotubes from lean subjects compared to myotubes from severely obese 238
subjects (Figure 2B), and the EPS-induced effect on oleic acid oxidation correlated also 239
negatively with the BMI of the subjects irrespective of donor group (Figure 2C). Mitochondrial 240
content shown as MitoTracker®
intensity related to nuclei was significantly increased by EPS in 241
myotubes from L-nD subjects (Figure 2D), but not in myotubes from severely obese subjects 242
(SO-nD, P = 0.076; SO-T2D, P = 0.32). Also the overall expression levels of proteins involved 243
in mitochondrial oxidative phosphorylation (OXPHOS proteins) were significantly increased by 244
EPS in myotubes from L-nD subjects (Figure 2E, F). Without EPS, lipid droplet number (Figure 245
2G) and neutral lipid content (data not shown) measured with Bodipy 493/503 were not different 246
between the myotubes from lean non-diabetic and severely obese subjects, or between myotubes 247
from severely obese non-diabetic and diabetic subjects. EPS revealed no further differences in 248
lipid droplet number between the groups (Figure 2G). In line with this, cellular uptake of oleic 249
acid, assessed as the sum of cell-associated and CO2-trapped radioactivity was not affected by 250
EPS in neither of the donor groups (Figure 2H). 251
252
13
Effect of EPS on oleic acid metabolism in the presence of PPARδ activation 253
To examine whether the PPARδ agonist GW501516 and exercise could act synergistically in our 254
cell model, myotubes were exposed to both EPS and GW501516. PPARδ activation increased 255
oleic acid oxidation in myotubes from both lean and severely obese subjects, whereas no further 256
increase with GW501516 and EPS in combination compared to GW501516 alone (Figure 3A) 257
was seen. Cellular uptake of oleic acid was increased after GW501516 treatment in myotubes 258
from all three donor groups, whereas there was no further increase with GW501516 and EPS in 259
combination (Figure 3B). Although only studied in myotubes established from lean non-diabetic 260
subjects, mitochondrial content measured as MitoTracker®
intensity was not further increased in 261
cells treated with both GW501516 and EPS compared to EPS alone (Figure 3C). 262
Effect of EPS on slow-oxidative (MHCI) fiber type 263
We wanted to investigate the effect of EPS on expressions of gene and protein for type I fibers 264
(MYH7, the gene that regulates protein expression of MHCI). After EPS, MYH7 gene expression 265
was reduced in myotubes from SO-T2D subjects (Figure 4A). Furthermore, the EPS effect on 266
gene expression of MYH7 in myotubes correlated negatively with fasting plasma glucose (Figure 267
4B) and HbA1c (Figure 4C) levels of the subjects. However, results obtained for protein 268
expression of MHCI (Figure 4D) showed no significant differences between the donor groups. 269
Effect of EPS on gene expression of IL-6 and IL-8 270
To investigate whether the EPS-induced gene regulations of myokines seen in myotubes from 271
lean non-diabetic subjects (48) also occurred in myotubes originating from severely obese 272
subjects, qPCR on selected genes was performed. Gene expression of IL-6 was increased after 273
EPS in myotubes established from L-nD and SO-nD subjects (Figure 5A). Furthermore, EPS-274
14
induced effect on IL-6 gene expression in myotubes correlated negatively with fasting plasma 275
glucose (Figure 5B) as well as HbA1c (r = -0.60, P < 0.05) levels of the subjects. Similar results 276
were also obtained for IL-8; although the EPS increased IL-8 expression was not significant 277
(Figure 5C). In line with this, effect of EPS on gene expression of IL-8 also correlated negatively 278
with fasting plasma glucose levels of the subjects (Figure 5D). 279
280
15
DISCUSSION 281
In this study, we show that insulin sensitivity was increased in myotubes established from 282
severely obese subjects after EPS. Furthermore, EPS enhanced oxidative capacity of glucose in 283
myotubes from all subjects, while oleic acid oxidation and mitochondrial content were only 284
improved in myotubes from lean subjects. Oleic acid oxidation was also increased after 285
GW501516 treatment in myotubes from all subjects, whereas combination of GW501516 286
treatment and EPS showed no additional effect on oleic acid oxidation. Of particular interest, the 287
impact of EPS on gene expressions of IL-6, IL-8 and was different in myotubes originating from 288
lean and severely obese non-diabetic subjects compared to myotubes from severely obese 289
diabetic subjects. EPS reduced mRNA expression of slow fiber-type marker (MYH7) in 290
myotubes from diabetic subjects, while protein expression of this marker was not affected by EPS 291
in neither of the donor groups. 292
Our findings suggest that human myotubes display the same phenotype as intact muscle in vivo, 293
in accordance to other studies (17, 19, 24). The precise mechanisms by which myotubes are able 294
to retain the in vivo characteristics are not known. However, a combination of genetic and 295
epigenetic mechanisms is probably involved, and this has been reviewed in a recent paper (1). 296
For example, epigenetic regulation of skeletal muscle stem cells and skeletal muscle 297
differentiation, exercise, diet and a family history of T2D, have all been described to influence 298
DNA methylation in human skeletal muscle, and these are traits that might follow the isolated 299
satellite cells into their corresponding cultured myotubes (1). 300
Exercise increases insulin sensitivity in vivo (23, 46), and in line with this, we have shown here 301
that EPS can increase insulin sensitivity in insulin-resistant myotubes from severely obese 302
16
diabetic subjects. The observed effect on insulin sensitivity was more evident in myotubes from 303
severely obese subjects, which is consistent with other studies reporting greater exercise-induced 304
changes in insulin sensitivity in subjects who were more insulin-resistant at baseline (5, 20), and 305
more evident in obese men compared to lean men (20). This suggests that interventions to 306
increase physical activity may be particularly effective at improving insulin sensitivity in 307
population groups who are more insulin resistant or have an increased predisposition to insulin 308
resistance. Lack of EPS-induced increase in insulin sensitivity in myotubes from lean non-309
diabetic subjects could be explained by maximal responsiveness to insulin in those cells per se 310
and limited capacity to respond further. In agreement with other studies reporting enhanced 311
carbohydrate oxidation after exercise in obese subjects (9), and in subjects with T2D (50), we 312
showed an increase in glucose oxidation after EPS in myotubes from all three donor groups. In 313
contrast, we have previously (36), and in the present study shown that mitochondrial content was 314
increased after EPS in myotubes from lean non-diabetic subjects, and this was followed by 315
increased rate of oleic acid oxidation. In this study, however, we showed that this is not the case 316
in myotubes from both groups of severely obese subjects. These data are in contrast to studies 317
reporting an increase in muscle ex vivo palmitate oxidation in obese subjects after in vivo exercise 318
(33). The discrepancy may to some extent be explained by differences between in vivo and in 319
vitro exercise models. Without EPS, there was no difference in basal lipid content between 320
myotubes from the three donor groups, excluding the possibility that the absence of EPS effect on 321
oleic acid oxidation was due to label dilution when using a labelled fatty acid as a measurement 322
of fatty acid oxidation. At resting state, the current consensus is that fatty acid oxidation is 323
reduced in obese versus lean muscle (6, 26). However, some studies have also reported similar 324
fatty acid oxidation in myotubes from lean and obese, diabetic subjects (49) and even higher 325
oxidation in obese than lean muscle (3). The reason behind this discrepancy is unclear, but may 326
17
be a result of different subgroups of obese populations studied. It is an ongoing debate whether 327
the impairment in oxidative capacity in obese and insulin-resistant subjects is due to lower 328
mitochondrial content or intrinsic mitochondrial dysfunction (54). Although it has been shown 329
that exercise improves both mitochondrial content and intrinsic mitochondrial function in obese 330
and insulin-resistant subjects (43), it has also been reported no changes in key regulators of 331
mitochondrial biogenesis in skeletal muscles in diabetic men after in vivo exercise (12). 332
Consistent with this, in our exercise model, myotubes from subjects with higher BMI were less 333
responsive to exercise-induced effects on fatty acid oxidation than myotubes from lean subjects. 334
It has been suggested that insulin resistance in obesity and T2D is associated with intracellular 335
accumulation of lipid in skeletal muscles (29). Consequently, much focus has been on the 336
possibility of increasing lipid utilization by exercise to avoid lipid accumulation. However, 337
evidence has emerged that increased lipid oxidation impair glucose uptake by metabolic 338
feedback, as suggested by the Randle cycle (reviewed in (29)). In line with this, we have shown 339
that EPS was able to improve insulin sensitivity and glucose oxidation in myotubes from both 340
groups of severely obese subjects without having impact on lipid oxidation. 341
Gene regulations involved in exercise adaptation are complex (14, 48), but genes regulated by 342
PPARδ may be involved (15). It has also been proposed that PPARδ agonists and exercise 343
training synergistically increase the proportion of type 1 fibers (MHCI) in adult mice (35). 344
However, selective biomarkers for fatty acid β-oxidation were no further induced with exercise 345
compared to GW501516 (35), which is consistent with our findings that oleic acid oxidation were 346
no further increased when myotubes were treated with a combination of GW501516 and EPS. 347
In response to acute exercise, an increase of IL-6 mRNA expression has been detected in muscle 348
during exercise and in the post-exercise period in both lean and obese subjects (11, 51). In 349
18
contrast to myotubes from lean and obese non-diabetic subjects, EPS did not increase mRNA 350
expression of IL-6 in myotubes from obese diabetic subjects. In support of our findings, other 351
studies have also reported no effect on IL-6 mRNA levels in muscle biopsies from obese diabetic 352
subjects (52) and in plasma from diabetic mice after in vivo exercise (8). This may reflect an 353
inherent abnormal IL-6 response in insulin resistant skeletal muscle (27, 47). It has previously 354
been shown that EPS increased gene expression of IL-8 in lean non-diabetic myotubes (48), and 355
our current data indicate that the impact of EPS on gene expression of IL-8 differs in myotubes 356
from severely obese non-diabetic subjects compared to diabetic subjects. Exercise-derived IL-8 is 357
postulated to stimulate angiogenesis in skeletal muscles (39), but the biological role of muscle-358
derived IL-8 remains to be clarified. Despite vast research on myokines the past decade, more 359
research is needed in order to clarify whether there is an altered myokine response in skeletal 360
muscles from subjects with disturbed metabolic status. 361
In summary, by applying chronic, low-frequency EPS on cultured myotubes established from 362
three different donor groups, lean non-diabetic subjects and severely obese subjects with and 363
without T2D, we observed an increase in insulin sensitivity with no improvement of lipid 364
oxidation after EPS in myotubes from both groups of severely obese subjects. These findings 365
were associated with BMI of the subjects suggesting an effect linked to obesity and indicating 366
that improving insulin sensitivity is not solely depended on combating lipid accumulation with 367
increased oxidative capacity of lipids. Furthermore, we observed a reduced or no effect of EPS on 368
gene expression of the myokines IL-6 and IL-8 in myotubes from severely obese diabetic 369
subjects. These findings were associated with fasting plasma glucose levels of the subjects 370
suggesting an effect linked to the diabetic phenotype. Taken together, these data show that 371
19
myotubes from different donor groups responded differently to EPS, suggesting that this effect 372
may reflect the in vivo characteristics of the donor groups. 373
374
ACKNOWLEDGEMENTS 375
The authors thank Terje Grønås (Electronics Lab, Institute of Chemistry, University of Oslo) for 376
support and technical assistance. We are also thankful to Gerbrand Koster and Oddmund Bakke 377
from the NORMIC-UiO imaging platform, Department of Molecular Biosciences, University of 378
Oslo, for support, use of equipment and for excellent technical assistance. 379
GRANTS 380
This work was founded by the University of Oslo, Diabetesforbundets forskningsfond and 381
Anders Jahres fond til vitenskapens fremme. 382
383
20
References 384
1. Aas V, Bakke SS, Feng YZ, Kase ET, Jensen J, Bajpeyi S, Thoresen GH, and Rustan 385
AC. Are cultured human myotubes far from home? Cell and tissue research 354: 671-682, 2013. 386
2. Akerstrom T, Steensberg A, Keller P, Keller C, Penkowa M, and Pedersen BK. 387
Exercise induces interleukin-8 expression in human skeletal muscle. The Journal of physiology 388
563: 507-516, 2005. 389
3. Ara I, Larsen S, Stallknecht B, Guerra B, Morales-Alamo D, Andersen JL, Ponce-390
Gonzalez JG, Guadalupe-Grau A, Galbo H, Calbet JA, and Helge JW. Normal 391
mitochondrial function and increased fat oxidation capacity in leg and arm muscles in obese 392
humans. International journal of obesity 35: 99-108, 2011. 393
4. Bakke S, Feng Y, Nikolić N, Kase E, Moro C, Stensrud C, Damlien L, Ludahl M, 394
Sandbu R, Solheim B, Rustan A, Hjelmesæth J, Thoresen G, and Aas V. Myotubes from 395
severely obese type 2 diabetic subjects accumulate less lipids and show higher lipolytic rate than 396
myotubes from severely obese non-diabetic subjects. Submitted PLOS ONE journal 05.09.2014. 397
5. Barwell ND, Malkova D, Moran CN, Cleland SJ, Packard CJ, Zammit VA, and Gill 398
JM. Exercise training has greater effects on insulin sensitivity in daughters of patients with type 399
2 diabetes than in women with no family history of diabetes. Diabetologia 51: 1912-1919, 2008. 400
6. Berggren JR, Boyle KE, Chapman WH, and Houmard JA. Skeletal muscle lipid 401
oxidation and obesity: influence of weight loss and exercise. American journal of physiology 402
Endocrinology and metabolism 294: E726-732, 2008. 403
7. Berggren JR, Tanner CJ, and Houmard JA. Primary cell cultures in the study of 404
human muscle metabolism. Exercise and sport sciences reviews 35: 56-61, 2007. 405
8. Bortolon JR, Silva Junior AJ, Murata GM, Newsholme P, Curi R, Pithon-Curi TC, 406
and Hatanaka E. Persistence of inflammatory response to intense exercise in diabetic rats. 407
Experimental diabetes research 2012: 213986, 2012. 408
9. Bourlier V, Saint-Laurent C, Louche K, Badin PM, Thalamas C, de Glisezinski I, 409
Langin D, Sengenes C, and Moro C. Enhanced glucose metabolism is preserved in cultured 410
primary myotubes from obese donors in response to exercise training. The Journal of clinical 411
endocrinology and metabolism 98: 3739-3747, 2013. 412
10. Carey AL, Steinberg GR, Macaulay SL, Thomas WG, Holmes AG, Ramm G, 413
Prelovsek O, Hohnen-Behrens C, Watt MJ, James DE, Kemp BE, Pedersen BK, and 414
Febbraio MA. Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose 415
uptake and fatty acid oxidation in vitro via AMP-activated protein kinase. Diabetes 55: 2688-416
2697, 2006. 417
11. Christiansen T, Bruun JM, Paulsen SK, Olholm J, Overgaard K, Pedersen SB, and 418
Richelsen B. Acute exercise increases circulating inflammatory markers in overweight and obese 419
compared with lean subjects. European journal of applied physiology 113: 1635-1642, 2013. 420
12. Chung N, Kreutz T, Schiffer T, Opitz D, Hermann R, Gehlert S, Bloch W, Brixius K, 421
and Brinkmann C. Training-induced alterations of skeletal muscle mitochondrial biogenesis 422
proteins in non-insulin-dependent type 2 diabetic men. Canadian journal of physiology and 423
pharmacology 90: 1634-1641, 2012. 424
13. Corpeleijn E, Hessvik NP, Bakke SS, Levin K, Blaak EE, Thoresen GH, Gaster M, 425
and Rustan AC. Oxidation of intramyocellular lipids is dependent on mitochondrial function and 426
the availability of extracellular fatty acids. American journal of physiology Endocrinology and 427
metabolism 299: E14-22, 2010. 428
21
14. Egan B, and Zierath JR. Exercise metabolism and the molecular regulation of skeletal 429
muscle adaptation. Cell metabolism 17: 162-184, 2013. 430
15. Ehrenborg E, and Krook A. Regulation of skeletal muscle physiology and metabolism 431
by peroxisome proliferator-activated receptor. Pharmacological Reviews 61: 373-393, 2009. 432
16. Feng YZ, Nikolic N, Bakke SS, Boekschoten MV, Kersten S, Kase ET, Rustan AC, 433
and Thoresen GH. PPARdelta activation in human myotubes increases mitochondrial fatty acid 434
oxidative capacity and reduces glucose utilization by a switch in substrate preference. Archives of 435
physiology and biochemistry 120: 12-21, 2014. 436
17. Gaster M. Metabolic flexibility is conserved in diabetic myotubes. Journal of lipid 437
research 48: 207-217, 2007. 438
18. Gaster M, Kristensen SR, Beck-Nielsen H, and Schroder HD. A cellular model system 439
of differentiated human myotubes. APMIS : acta pathologica, microbiologica, et immunologica 440
Scandinavica 109: 735-744. 441
19. Gaster M, Petersen I, Hojlund K, Poulsen P, and Beck-Nielsen H. The diabetic 442
phenotype is conserved in myotubes established from diabetic subjects: evidence for primary 443
defects in glucose transport and glycogen synthase activity. Diabetes 51: 921-927, 2002. 444
20. Gill JM, and Malkova D. Physical activity, fitness and cardiovascular disease risk in 445
adults: interactions with insulin resistance and obesity. Clinical science 110: 409-425, 2006. 446
21. Glund S, and Krook A. Role of interleukin-6 signalling in glucose and lipid metabolism. 447
Acta physiologica 192: 37-48, 2008. 448
22. Harridge SD. Plasticity of human skeletal muscle: gene expression to in vivo function. 449
Experimental physiology 92: 783-797, 2007. 450
23. Hawley JA, and Lessard SJ. Exercise training-induced improvements in insulin action. 451
Acta physiologica 192: 127-135, 2008. 452
24. Henry RR, Abrams L, Nikoulina S, and Ciaraldi TP. Insulin action and glucose 453
metabolism in nondiabetic control and NIDDM subjects. Comparison using human skeletal 454
muscle cell cultures. Diabetes 44: 936-946, 1995. 455
25. Hessvik NP, Bakke SS, Fredriksson K, Boekschoten MV, Fjorkenstad A, Koster G, 456
Hesselink MK, Kersten S, Kase ET, Rustan AC, and Thoresen GH. Metabolic switching of 457
human myotubes is improved by n-3 fatty acids. Journal of lipid research 51: 2090-2104, 2010. 458
26. Hulver MW, Berggren JR, Cortright RN, Dudek RW, Thompson RP, Pories WJ, 459
MacDonald KG, Cline GW, Shulman GI, Dohm GL, and Houmard JA. Skeletal muscle lipid 460
metabolism with obesity. American journal of physiology Endocrinology and metabolism 284: 461
E741-747, 2003. 462
27. Jiang LQ, Duque-Guimaraes DE, Machado UF, Zierath JR, and Krook A. Altered 463
response of skeletal muscle to IL-6 in type 2 diabetic patients. Diabetes 62: 355-361, 2013. 464
28. Kase ET, Nikolic N, Bakke SS, Bogen KK, Aas V, Thoresen GH, and Rustan AC. 465
Remodeling of oxidative energy metabolism by galactose improves glucose handling and 466
metabolic switching in human skeletal muscle cells. PloS one 8: e59972, 2013. 467
29. Kiens B, Alsted TJ, and Jeppesen J. Factors regulating fat oxidation in human skeletal 468
muscle. Obesity reviews : an official journal of the International Association for the Study of 469
Obesity 12: 852-858, 2011. 470
30. Kim JY, Hickner RC, Cortright RL, Dohm GL, and Houmard JA. Lipid oxidation is 471
reduced in obese human skeletal muscle. Am J Physiol-Endoc M 279: E1039-E1044, 2000. 472
31. Lambernd S, Taube A, Schober A, Platzbecker B, Gorgens SW, Schlich R, 473
Jeruschke K, Weiss J, Eckardt K, and Eckel J. Contractile activity of human skeletal muscle 474
22
cells prevents insulin resistance by inhibiting pro-inflammatory signalling pathways. 475
Diabetologia 55: 1128-1139, 2012. 476
32. Lillioja S, Young AA, Culter CL, Ivy JL, Abbott WG, Zawadzki JK, Yki-Jarvinen H, 477
Christin L, Secomb TW, and Bogardus C. Skeletal muscle capillary density and fiber type are 478
possible determinants of in vivo insulin resistance in man. The Journal of clinical investigation 479
80: 415-424, 1987. 480
33. Louche K, Badin PM, Montastier E, Laurens C, Bourlier V, de Glisezinski I, 481
Thalamas C, Viguerie N, Langin D, and Moro C. Endurance exercise training up-regulates 482
lipolytic proteins and reduces triglyceride content in skeletal muscle of obese subjects. The 483
Journal of clinical endocrinology and metabolism 98: 4863-4871, 2013. 484
34. Miyake T, McDermott JC, and Gramolini AO. A method for the direct identification 485
of differentiating muscle cells by a fluorescent mitochondrial dye. PloS one 6: e28628, 2011. 486
35. Narkar VA, Downes M, Yu RT, Embler E, Wang YX, Banayo E, Mihaylova MM, 487
Nelson MC, Zou Y, Juguilon H, Kang H, Shaw RJ, and Evans RM. AMPK and PPARdelta 488
agonists are exercise mimetics. Cell 134: 405-415, 2008. 489
36. Nikolic N, Bakke SS, Kase ET, Rudberg I, Flo Halle I, Rustan AC, Thoresen GH, 490
and Aas V. Electrical pulse stimulation of cultured human skeletal muscle cells as an in vitro 491
model of exercise. PloS one 7: e33203, 2012. 492
37. O'Gorman DJ, and Krook A. Exercise and the treatment of diabetes and obesity. The 493
Medical clinics of North America 95: 953-969, 2011. 494
38. Pedersen BK. Exercise-induced myokines and their role in chronic diseases. Brain, 495
behavior, and immunity 25: 811-816, 2011. 496
39. Pedersen BK. Muscle as a secretory organ. Comprehensive Physiology 3: 1337-1362, 497
2013. 498
40. Pedersen BK. Muscular interleukin-6 and its role as an energy sensor. Medicine and 499
science in sports and exercise 44: 392-396, 2012. 500
41. Pedersen BK, and Febbraio MA. Muscle as an endocrine organ: focus on muscle-501
derived interleukin-6. Physiological reviews 88: 1379-1406, 2008. 502
42. Pedersen BK, and Febbraio MA. Muscles, exercise and obesity: skeletal muscle as a 503
secretory organ. Nature reviews Endocrinology 8: 457-465, 2012. 504
43. Phielix E, Meex R, Moonen-Kornips E, Hesselink MK, and Schrauwen P. Exercise 505
training increases mitochondrial content and ex vivo mitochondrial function similarly in patients 506
with type 2 diabetes and in control individuals. Diabetologia 53: 1714-1721, 2010. 507
44. Raschke S, Eckardt K, Bjorklund Holven K, Jensen J, and Eckel J. Identification and 508
validation of novel contraction-regulated myokines released from primary human skeletal muscle 509
cells. PloS one 8: e62008, 2013. 510
45. Richter EA, Garetto LP, Goodman MN, and Ruderman NB. Muscle glucose 511
metabolism following exercise in the rat: increased sensitivity to insulin. The Journal of clinical 512
investigation 69: 785-793, 1982. 513
46. Rockl KS, Witczak CA, and Goodyear LJ. Signaling mechanisms in skeletal muscle: 514
acute responses and chronic adaptations to exercise. IUBMB life 60: 145-153, 2008. 515
47. Scheele C, Nielsen S, Kelly M, Broholm C, Nielsen AR, Taudorf S, Pedersen M, 516
Fischer CP, and Pedersen BK. Satellite cells derived from obese humans with type 2 diabetes 517
and differentiated into myocytes in vitro exhibit abnormal response to IL-6. PloS one 7: e39657, 518
2012. 519
23
48. Scheler M, Irmler M, Lehr S, Hartwig S, Staiger H, Al-Hasani H, Beckers J, de 520
Angelis MH, Haring HU, and Weigert C. Cytokine response of primary human myotubes in an 521
in vitro exercise model. American journal of physiology Cell physiology 305: C877-886, 2013. 522
49. Sparks LM, Bosma M, Brouwers B, van de Weijer T, Bilet L, Schaart G, Moonen-523
Kornips E, Eichmann TO, Lass A, Hesselink MK, and Schrauwen P. Reduced incorporation 524
of Fatty acids into triacylglycerol in myotubes from obese individuals with type 2 diabetes. 525
Diabetes 63: 1583-1593, 2014. 526
50. Sparks LM, Johannsen NM, Church TS, Earnest CP, Moonen-Kornips E, Moro C, 527
Hesselink MK, Smith SR, and Schrauwen P. Nine months of combined training improves ex 528
vivo skeletal muscle metabolism in individuals with type 2 diabetes. The Journal of clinical 529
endocrinology and metabolism 98: 1694-1702, 2013. 530
51. Steensberg A, van Hall G, Osada T, Sacchetti M, Saltin B, and Klarlund Pedersen B. 531
Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-532
induced increase in plasma interleukin-6. The Journal of physiology 529 Pt 1: 237-242, 2000. 533
52. Tantiwong P, Shanmugasundaram K, Monroy A, Ghosh S, Li M, DeFronzo RA, 534
Cersosimo E, Sriwijitkamol A, Mohan S, and Musi N. NF-kappaB activity in muscle from 535
obese and type 2 diabetic subjects under basal and exercise-stimulated conditions. American 536
journal of physiology Endocrinology and metabolism 299: E794-801, 2010. 537
53. Teran-Garcia M, Rankinen T, Koza RA, Rao DC, and Bouchard C. Endurance 538
training-induced changes in insulin sensitivity and gene expression. American journal of 539
physiology Endocrinology and metabolism 288: E1168-1178, 2005. 540
54. Toledo FGS, and Goodpaster BH. The role of weight loss and exercise in correcting 541
skeletal muscle mitochondrial abnormalities in obesity, diabetes and aging. Mol Cell Endocrinol 542
379: 30-34, 2013. 543
55. Wolsk E, Mygind H, Grondahl TS, Pedersen BK, and van Hall G. IL-6 selectively 544
stimulates fat metabolism in human skeletal muscle. American journal of physiology 545
Endocrinology and metabolism 299: E832-840, 2010. 546
56. You T, Arsenis NC, Disanzo BL, and Lamonte MJ. Effects of exercise training on 547
chronic inflammation in obesity : current evidence and potential mechanisms. Sports Med 43: 548
243-256, 2013. 549
550
551
552
24
Figure legends 553
554
555
Figure 1- EPS improved insulin sensitivity in myotubes derived from severely obese subjects. 556
EPS was applied to cultured myotubes for the last 48 h of the differentiation period. A, B: After 557
termination of EPS, myotubes were incubated for 15 min in presence or absence of 100 nmol/L 558
insulin, and immunoblotting analysis with antibodies against pAkt (Ser473) and total-Akt were 559
performed (n = 4-5). A: pAkt/total Akt without insulin. B: Insulin-stimulated pAkt/total Akt. C, D: 560
After termination of EPS, glycogen synthesis was measured as [14
C]glucose (1 mmol/L) 561
incorporation into glycogen in presence or absence of 100 nmol/L insulin for 3 h (n = 6-8). C: 562
Glycogen synthesis without insulin. D: Insulin-stimulated glycogen synthesis. EPS-induced 563
effect on insulin-stimulated pAkt/total Akt (E, n = 13) and glycogen synthesis (F, n = 21) in the 564
myotubes correlated positively with BMI of the donor subjects. *P ˂ 0.05 vs. control. 565
Figure 2- EPS improved oxidative capacity of human myotubes. The myotubes were electrically 566
stimulated for 48 h; glucose and oleic acid oxidation, mitochondrial staining and lipid droplets 567
were measured after termination of EPS. A: Glucose oxidation. Myotubes were exposed to 568
[14
C]glucose (1 mmol/L) for 3 h before CO2 assessment (n = 6-7). B: Oleic acid oxidation. 569
Myotubes were exposed to [14
C]oleic acid (100 µmol/L) for 2 h before CO2 assessment (n = 7-8). 570
C: EPS-induced effect on oleic acid oxidation correlated negatively with BMI of the subjects (n = 571
21). D: The myotubes were stained for mitochondrial content with MitoTracker®
Red FM, and 572
nuclei with Hoechst 33258. Data are shown as MitoTracker intensity related to nuclei (n = 5-6). E: 573
Expression of proteins involved in mitochondrial oxidative phosphorylation, OXPHOS (Complex 574
I subunit NDUFB8, Complex II subunit, Complex III subunit core 2, Complex IV subunit II and 575
ATP synthase subunit α). Expression levels were normalized to α-tubulin (n = 4-6). Linear mixed 576
model was performed for OXPHOS experiments. F: Representative immunoblots from one 577
25
experiment (L-nD). Ctr; control. G: The myotubes were stained for neutral lipids with Bodipy 578
493/503. Data are shown as lipid droplets related to nuclei. H: Cellular uptake of oleic acid was 579
assessed as the sum of cell-associated and CO2-trapped radioactivity (n = 7-8). *P < 0.05 vs. 580
control. #P < 0.05 vs. L-nD. 581
Figure 3- Effect of EPS combined with PPARδ activation on oleic acid metabolism. Myotubes 582
were treated with 10 nmol/L GW501516 for 96 h and EPS was applied to the cells for the last 48 583
h of the treatment period. A, B: After termination of EPS, myotubes were exposed to [14
C]oleic 584
acid (100 µmol/L) for 2 h. A: Oleic acid oxidation (n=5-10). B: Cellular uptake of oleic acid, 585
assessed as the sum of cell-associated and CO2-trapped radioactivity (n=5-7). C: After 586
termination of EPS, the myotubes were stained for mitochondrial content with MitoTracker®
Red 587
FM, and nuclei with Hoechst 33258. Data are shown as MitoTracker intensity related to nuclei 588
and normalized to unstimulated control cells (n = 5-6). *P < 0.05 vs. control. 589
Figure 4- Effect of EPS on gene and protein expression of MHCI. The myotubes were 590
electrically stimulated for 48 h. A: After termination of EPS, expression of MYH7 (the gene that 591
regulates protein expression of myosin heavy chain type I (MHCI)) was measured by qPCR and 592
compared relative to the housekeeping genes 36B4 and GAPDH (n =5-6). B, C: EPS effect on 593
gene expression of MYH7 correlated negatively with fasting plasma glucose (B) and HbA1c (C) 594
of the subjects (n =16). D: Immunoblotting analysis with antibodies against MHCI, related to β-595
actin, presented relative to unstimulated control.*P < 0.05 vs. control. 596
Figure 5- Effect of EPS on gene expression of IL-6 and IL-8. The myotubes were electrically 597
stimulated for 48 h and harvested after termination of EPS. Expression of IL-6 (A) and IL-8 (C) 598
were measured by qPCR and studied relative to the housekeeping genes 36B4 and GAPDH. 599
26
Fasting plasma glucose levels were inversely related to EPS effect on gene expressions of IL-6 (B, 600
n = 22) and IL-8 (D, n = 19). *P < 0.05 vs. control. 601
602
603
Table 1- Clinical characteristics of biopsy donors
L-nD (n = 14) SO-nD (n = 9) SO-T2D (n = 9)
Age (years) 49 ± 4 41 ± 2 48 ± 3
BMI (kg/m2) 24.3± 0.9 42.0 ± 1.7* 44.6 ± 2.2*
Fasting glucose (mmol/l) 5.6 ± 0.3 4.8 ± 0.1 8.2 ± 0.5†
HbA1c (%) - 5.5 ± 0.1 7.2 ± 0.6#
Insulin pmol/l - 89.4 ± 16 62.4 ± 18
TAG (mmol/l) 1.0 ± 0.1 1.6 ± 0.2* 2.0 ± 0.3*
HDL (mmol/l) 1.6 ± 0.1 1.1 ± 0.1* 1.0 ± 0.1*
Data are presented as mean ± SEM. L-nD; lean non-diabetic, SO-nD; severely obese non-diabetic,
SO-T2D; severely obese with type 2 diabetes. HbA1c and plasma insulin were not measured in the
lean non-diabetic cohort. *Significantly different from the lean group. †Significantly (P < 0.05)
different from both of the non-diabetic groups. #Significantly different from SO-nD. BMI; body
mass index, HbA1c; glycosylated hemoglobin, HDL; high-density lipoprotein, TAG;
triacylglycerol